From the Department of Radiology (G.X.W., P.V.P., J.O.S., F.J.F., E.J.F.), Division of General Internal Medicine (T.P.B., S.P.L.), and Department of Psychiatry (E.R.P.), Harvard Medical School, Massachusetts General Hospital, 55 Fruit St, Founders 202, Boston, MA 02114; and Institute for Technology Assessment (P.V.P.), Mongan Institute Health Policy Center (E.R.P.), and Tobacco Research and Treatment Center (E.R.P., T.P.B.), Massachusetts General Hospital, Boston, Mass.
Radiology. 2019 Feb;290(2):278-287. doi: 10.1148/radiol.2018180212. Epub 2019 Jan 8.
Lung cancer remains the leading cause of cancer mortality in the United States. Lung cancer screening (LCS) with low-dose CT reduces mortality among high-risk current and former smokers and has been covered by public and private insurers without cost sharing since 2015. Patients and referring providers confront numerous barriers to participation in screening. To best serve in multidisciplinary efforts to expand LCS nationwide, radiologists must be knowledgeable of these challenges. A better understanding of the difficulties confronted by other stakeholders will help radiologists continue to collaboratively guide the growth of LCS programs in their communities. This article reviews barriers to participation in LCS for patients and referring providers, as well as possible solutions and interventions currently underway.
肺癌仍然是美国癌症死亡的主要原因。自 2015 年以来，低剂量 CT 肺癌筛查（LCS）降低了高危现吸烟者和前吸烟者的死亡率，并已被公共和私人保险公司承保，无需分担费用。患者和转诊医生在参与筛查方面面临着许多障碍。为了在全国范围内扩大肺癌筛查的多学科努力中提供最佳服务，放射科医生必须了解这些挑战。更好地了解其他利益相关者所面临的困难将有助于放射科医生继续合作指导他们所在社区的肺癌筛查项目的发展。本文回顾了患者和转诊医生参与 LCS 的障碍，以及目前正在进行的可能的解决方案和干预措施。
